Related Experiment Video

Updated: Sep 6, 2025

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate
07:31

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

3.8K

Oncostatin M Receptor as a Therapeutic Target for Radioimmune Therapy in Synovial Sarcoma

Sarah McCollum1, Austen Kalivas1, Matthew Kirkham1

  • 1Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, Idaho State University, Pocatello, ID 83209, USA.

Pharmaceuticals (Basel, Switzerland)
|June 24, 2022
PubMed

Insights

Oncostatin M receptor (OSMR) is upregulated in synovial sarcoma (SS), a rare pediatric cancer. Targeted radioimmune therapy against OSMR shows promise as a novel treatment for this challenging disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunology

Background:

  • Synovial sarcoma (SS) is a pediatric muscle cancer with limited therapeutic options.
  • Low mutational burden in SS complicates treatment strategies.
  • Upregulated inflammatory pathways, including oncostatin M receptor (OSMR), are observed in some SS cases.

Purpose of the Study:

  • To investigate OSMR as a potential therapeutic target in synovial sarcoma.
  • To develop and evaluate a novel radioimmune therapy for OSMR-expressing SS.

Main Methods:

  • RNA sequencing and quantitative PCR to assess OSMR expression in SS.
  • Western blot and immunohistochemistry in mouse models to confirm OSMR presence.
  • Synthesis and characterization of an OSMR-targeted radioimmune therapy drug.
  • Pharmacokinetic studies and biodistribution analysis in mouse models.

Main Results:

  • OSMR is significantly upregulated in synovial sarcoma tissues and mouse models.
  • The developed radioimmune therapy drug is stable and effectively binds OSMR.
  • The antibody conjugate demonstrated favorable pharmacokinetics and targeted primary and metastatic SS sites in vivo.

Conclusions:

  • OSMR represents a promising therapeutic target for synovial sarcoma.
  • OSMR-targeted radioimmune therapy offers a novel treatment strategy for patients with limited options.
Keywords:
OSMRRIToncologyradioimmune therapysarcomasynovial sarcoma

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models04:25

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

9.8K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

12.9K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
652
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K